Could your body shape predict radiation accuracy?
NCT ID NCT07676032
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study looks at whether a person's body composition—like muscle mass and body fat—affects how accurately they are positioned during radiation therapy. Researchers will measure body composition in 120–150 cancer patients before and during treatment, and track daily positioning errors. The goal is to see if body composition, beyond just weight, can help personalize how patients are immobilized for more precise radiation delivery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If body composition is found to predict setup errors, this could lead to personalized immobilization and imaging strategies for more precise radiotherapy.
- What could go wrong
- This is an observational study, not a treatment trial. It may find no meaningful link, or the results may not apply to other hospitals or patient groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 150 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with pathologically confirmed malignancies receiving radical or adjuvant intensity-modulated radiotherapy at Shijiazhuang People's Hospital.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Pathologically confirmed malignancy * Age ≥18 years * Receiving radical or adjuvant intensity-modulated radiotherapy (IMRT) with planned ≥25 fractions * Immobilized with thermoplastic mask * ECOG Performance Status 0-2 * Willing and able to provide written informed consent Exclusion Criteria: * Metal implants (pacemaker, artificial joints) affecting bioelectrical impedance analysis (BIA) measurements * Severe edema or ascites * Inability to cooperate with immobilization or CBCT scanning * Radiotherapy interruption \>5 fractions * Pregnancy or lactation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Malignant neoplasms are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug naderin may help patients fight infections during cancer and TB therapy
- New study aims to uncover why some women have worse sexual side effects from radiation
- New injection YKYY031 enters human testing for Hard-to-Treat cancers
- New robot arm takes on cancer surgery – first safety check begins
- New combo therapy aims to shrink kidney tumors in Late-Stage trial
- Belzutifan extension trial aims to extend lives in VHL and advanced cancer